2362015-67-4
Chemical Structure
Lonigutamab
Synonym(s): hz208F2-4
- CAS No.: 2362015-67-4
- Formula:N/A
- Molecular Weight:(145.12 kDa)
SMILES: [Lonigutamab]
Biological Activity: Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lonigutamab | 95.00% | Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MVT-5873 | 99.66% | MVT-5873 is a humanized antibody expressed in CHO cells, targeting Sialyl-Lewis A. MVT-5873 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for MVT-5873 can refer to Human IgG1 kappa, Isotype Control (HY-P99001). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Akla B, et al. Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. Mol Cancer Ther. 2020 Jan;19(1):168-177. [Content Brief]
- [2]. Pimenta EM, et al. Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. bioRxiv [Preprint]. 2025 Jan 24:2025.01.20.633920. [Content Brief]
Keywords
